129 related articles for article (PubMed ID: 26085061)
1. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
Bello E; Pellagatti A; Shaw J; Mecucci C; Kušec R; Killick S; Giagounidis A; Raynaud S; Calasanz MJ; Fenaux P; Boultwood J
Br J Haematol; 2015 Oct; 171(2):210-214. PubMed ID: 26085061
[TBL] [Abstract][Full Text] [Related]
2. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
3. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
Schneider RK; Ademà V; Heckl D; Järås M; Mallo M; Lord AM; Chu LP; McConkey ME; Kramann R; Mullally A; Bejar R; Solé F; Ebert BL
Cancer Cell; 2014 Oct; 26(4):509-20. PubMed ID: 25242043
[TBL] [Abstract][Full Text] [Related]
4. Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion.
Stalmann USA; Ticconi F; Snoeren IAM; Li R; Gleitz HFE; Cowley GS; McConkey ME; Wong AB; Schmitz S; Fuchs SNR; Sood S; Leimkühler NB; Martinez-Høyer S; Banjanin B; Root D; Brümmendorf TH; Pearce JE; Schuppert A; Bindels EMJ; Essers MA; Heckl D; Stiehl T; Costa IG; Ebert BL; Schneider RK
Blood Adv; 2022 Mar; 6(6):1780-1796. PubMed ID: 35016204
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the 5q- Syndrome.
Pellagatti A; Boultwood J
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015037. PubMed ID: 26075044
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Lee JH; List A; Sallman DA
Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
[TBL] [Abstract][Full Text] [Related]
8. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
9. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
[TBL] [Abstract][Full Text] [Related]
10. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
Hosono N
Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
12. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
[TBL] [Abstract][Full Text] [Related]
13. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
15. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
Wang L; Fidler C; Nadig N; Giagounidis A; Della Porta MG; Malcovati L; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
Haematologica; 2008 Jul; 93(7):994-1000. PubMed ID: 18508791
[TBL] [Abstract][Full Text] [Related]
17. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
18. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients.
Ou R; Huang J; Shen H; Liu Z; Zhu Y; Zhong Q; Zheng L; Yao M; She Y; Zhou S; Chen R; Li C; Zhang Q; Liu S
Leuk Res; 2017 Nov; 62():40-50. PubMed ID: 28982058
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
